Bulbitech qualified for the semifinal of EIT Health Catapult 2022-23. This competition showcases the most promising European startups in three categories – biotech, medtech, and digital health. There are 42 companies in total and Bulbitech is selected as one of 14 most promising in the Medtech category.
Each company in the seimfinal has got the opportunity to receive high-quality, individualised training to prepare for the next phase of contest, and will present their solutions to a public audience of healthcare professionals, industry experts, investors and many more.
This achievement opens up Bulbitech to more opportunities in raising capital and reaching out to key opinion leaders in relevant medical areas. Semifinals winners will get prizes from the contest sponsors, including the likes of Amazon Web Services, Astrazeneca, and Merck.
EIT Health was established in 2015 as a ‘knowledge and innovation community’ (KIC) of the European Institute of Innovation and Technology (EIT). The EIT is made up of various KICs who each focus on a different sector, or area, of innovation.
